PacBio Says It Will 'Vigorously' Defend Against Helicos' Patent Infringement Claims
September 07, 2010
PacBio Says It Will 'Vigorously' Defend Against Helicos' Patent Infringement Claims
"Helicos' patents are directed to methods used in their second-generation 'flush and scan' system, and even at that, do not represent the earliest publication of those concepts," said PacBio chairman and CEO Hugh Martin in a statement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- USPTO Grants PacBio's Reexamination Request of Four Helicos Patents; Helicos Files Response for First Patent
May 10, 2011 / In Sequence - PacBio to Expand Apps for SMRT Platform; Initial Focus on Cancer, Infectious Disease Sequencing
September 22, 2009 / In Sequence - Pocketing $68M, PacBio Remains on Track for Commercial Launch — and Possible IPO — in 2010
August 18, 2009 / In Sequence - Setting Sights on BRCA Testing Market, Helicos Develops Isolation-Free BRCA1 Sequencing Method
August 9, 2011 / Clinical Sequencing News - Launch of PacBio RS Drives Q2 Revenue, but Investors Raise Concerns Over Pace of Uptake
August 9, 2011 / In Sequence